Treatment of hidradenitis suppurativa with combination hypothalamic-pituitary-ovarian and adrenal suppression. A case report.
A 33-year-old woman with severe familial hidradenitis suppurativa of the vulva and perineum was treated with a combination of dexamethasone and a new synthetic gonadotropin releasing hormone agonist, leuprolide acetate. The clinical improvement paralleled the adrenal and ovarian suppression, as demonstrated by falling blood levels of testosterone, dehydroepiandrosterone sulfate, androstenedione and estradiol.
Camisa
C
C
Department of Dermatology, Cleveland Clinic Foundation, OH 44106.
Sexton
C
C
Friedman
C
C
D000328:Adult; D001050:Apocrine Glands; D003864:Depression, Chemical; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000627:therapeutic use; D006728:Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects*; D007249:Inflammation; D016729:Leuprolide; D008297:Male; D010053:Ovary / Q000187:drug effects*; D010902:Pituitary Gland / Q000187:drug effects*; D013492:Suppuration; D013543:Sweat Gland Diseases / Q000188:drug therapy*; D013545:Sweat Glands
D006728:Hormones; D007987:Gonadotropin-Releasing Hormone; D003907:Dexamethasone; D016729:Leuprolide